EL7.AI
StocksMediumUpdated×2•Originally published 13 October 2026•Updated 13 October 2026•
1 min read

Johnson & Johnson Raises 2026 Guidance Following Strong Q3 Results

Key Facts

1Johnson & Johnson announced Q3 2026 results and raised its full-year financial guidance.
2CEO Joaquin Duato stated that the strong performance reflects accelerating momentum in the company's focused portfolio.

Johnson & Johnson announced its Q3 2026 financial results and raised its full-year financial guidance, according to a statement on Business Wire. CEO Joaquin Duato stated that the strong performance reflects accelerating momentum within the company's focused portfolio.

JNJ closed at $263.73 on October 12, 2026, just prior to the guidance revision. The updated outlook follows sequential growth and advancements in MedTech innovations.

Latest Updates · 2

  1. Notable·

    Update: The company reported a decline in surgery revenue within its MedTech segment for the third quarter of 2026. Johnson & Johnson is currently working on initiatives to improve the segment's results and address this performance gap.

  2. Notable·

    Update: The company beat earnings estimates for the third quarter, though medical device sales faced headwinds from the conflict in the Middle East. Geopolitical tensions in the region weighed on device demand during the period.